Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV : an analysis of a multicentre cohort at 96 weeks
Suárez-García, Inés (Hospital Universitario Infanta Sofia (Madrid))
Alejos, Belén (Independent researcher (Madrid))
Moreno Prieto, Cristina (Universidad Europea de Madrid)
Martín Torres, Juan (Hospital Universitario 12 de Octubre (Madrid))
Masiá, Mar
García-Fraile Fraile, Lucio (Universidad Miguel Hernández de Elche)
Riera, Melchor (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Dalmau, David (Universitat de Barcelona. Departament de Medicina)
Rodríguez-Rosado, Rafael (Hospital Universitario Severo Ochoa (Madrid))
Muga, Roberto (Universitat Autònoma de Barcelona. Departament de Medicina)
Moreno, Santiago (Universidad de Alcalá)
Jarrín, Inma (Instituto de Carlos III)

Data:	2024
Resum:	To evaluate the long-term effectiveness, persistence and tolerability of dolutegravir (DTG)/lamivudine (3TC), compared with the most frequently prescribed first-line treatment regimens, among antiretroviral-naive people with HIV from CoRIS, a multicentre cohort in Spain, in 2018-23. We used multivariable regression models to compare viral suppression (VS) (HIV RNA viral load <50 copies/mL), change in CD4 cell counts, persistence and treatment discontinuations due to adverse events (AEs), at 96 (±24) weeks after treatment initiation. Of 2359 participants, DTG/3TC was prescribed in 472 (20. 0%), bictegravir/tenofovir alafenamide (TAF)/emtricitabine (FTC) in 1134 (48. 1%), DTG + tenofovir disoproxil fumarate/FTC in 300 (12. 7%), DTG/abacavir/3TC in 273 (11. 6%) and darunavir/cobicistat/TAF/FTC in 180 (7. 6%). At 96 weeks from treatment initiation, 94. 0% of participants initiating with DTG/3TC achieved VS, and the mean increase in CD4 cell counts was 295. 5 cells/μL (95% CI: 269. 9-321. 1). During the first 96 weeks after DTG/3TC initiation, 9. 8% and 1. 3% discontinued their initial regimen, overall and due to AEs, respectively. In multivariable analyses, we did not find significant differences in VS or increase in CD4 cell counts among participants initiating with DTG/3TC compared with other regimens. Initiating ART with a regimen other than DTG/3TC was associated with a higher risk of treatment discontinuation, overall and due to AEs. Among treatment-naive people with HIV from this large multicentre cohort, DTG/3TC had similar effectiveness and better persistence and tolerability than those of the most frequently prescribed first-line regimens at 96 weeks.
Ajuts:	ViiV Healthcare CB21/13/00091
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Journal of antimicrobial chemotherapy, Vol. 80 (december 2024) , p. 682-691, ISSN 1460-2091

DOI: 10.1093/jac/dkae456
PMID: 39710424

10 p, 474.0 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats